Fortress Biotech (FBIO)
(Real Time Quote from BATS)
$1.86 USD
+0.13 (7.51%)
Updated Aug 8, 2024 03:52 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 141 - 160 ( 317 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY- Multiple Shots on Goal - Use Weakness to Buy
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Multiple Shots on Goal ? Use Weakness to Buy
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 10/9/2020
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Huh? Say What? IV Tramadol Gets Unexpected and Bizarre CRL; Target Reduced to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Avenue?s Tramadol Gets Delayed on Opioid Stacking Concerns
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 10/2/2020
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Ximino/Targadox Tracker - Week ending 9/25/2020
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
CAEL-101 Goes Pivotal for AL Amyloidosis; Path Toward Alexion Acquisition Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J